Page 91 - 《中国药房》2024年15期
P. 91

sectable  hepatocellular  carcinoma (CARES-310):a  ran‐  meta-analysis  research  methodological  advances  series:
              domised,open-label,international phase 3 study[J]. Lan‐  13:network meta-analysis of survival data[J]. Chin J Evid
              cet,2023,402(10408):1133-1146.                      Based Cardiovasc Med,2021,13(6):649-652.
          [10]  KUDO  M.  Durvalumab  plus  tremelimumab  in  unresec-   [18]  唐密,杨燕,胡善联,等. 多准则决策分析应用于卫生决
              table  hepatocellular  carcinoma[J].  Hepatobiliary  Surg   策的理论基础与进展[J]. 中国卫生资源,2020,23(4):
              Nutr,2022,11(4):592-596.                            326-331.
          [11]  黄倩倩,王涛,康琪,等. 多准则决策分析在药物效益风                        TANG M,YANG Y,HU S L,et al. Theoretical basis and
              险评价领域的应用研究进展[J]. 中国新药杂志,2021,30                     progress  of  multi-criteria  decision  analysis  in  healthcare
              (22):2069-2074.                                     decision-making[J].  Chin  Health  Resour,2020,23(4):
              HUANG Q Q,WANG T,KANG Q,et al. Research pro-        326-331.
              gress  in  application  of  multi-criteria  decision  analysis  in   [19]  FINN R S,QIN S K,IKEDA M,et al. Atezolizumab plus
              the  field  of  drug  benefit-risk  assessment[J].  Chin  J  N   bevacizumab in unresectable hepatocellular carcinoma[J].
              Drugs,2021,30(22):2069-2074.                        N Engl J Med,2020,382(20):1894-1905.
          [12]  MORENO-CALDERÓN  A,TONG  T  S,THOKALA  P.    [20]  YAU T,PARK J W,FINN R S,et al. Nivolumab versus
              Multi-criteria  decision  analysis  software  in  healthcare         sorafenib  in  advanced  hepatocellular  carcinoma (Check‐
              priority setting:a systematic review[J]. Pharmacoeconomics,  Mate 459):a randomised,multicentre,open-label,phase 3
              2020,38(3):269-283.                                 trial[J]. Lancet Oncol,2022,23(1):77-90.
          [13]  DAI Z Q,XU S M,WU X,et al. Knowledge mapping of   [21]  LIU  K,ZHU Y W,ZHU  H.  Immunotherapy  or  targeted
              multicriteria decision analysis in healthcare:a bibliometric   therapy as the first-line strategies for unresectable hepato‐
              analysis[J]. Front Public Health,2022,10:895552.    cellular  carcinoma:a  network  meta-analysis  and  cost-
          [14]  何 玉 梅 ,聂 智 峰 ,李 薇 ,等 .  多 准 则 决 策 分 析 中 的         effectiveness  analysis[J].  Front  Immunol,2023,13:
              MACBETH方法与软件简介[J]. 医学新知,2023,33(2):                 1103055.
              110-119.                                       [22]  LI L,YANG S L,CHEN Y W,et al. Immune checkpoint
              HE  Y  M,NIE  Z  F,LI  W,et  al.  Introduction  to   inhibitors  plus  an  anti-VEGF  antibody  as  the  first-line
              MACBETH  methods  and  software  in  multi-criteria  deci‐  treatment for unresectable hepatocellular carcinoma:a net‐
              sion analysis[J]. N Med,2023,33(2):110-119.         work  meta-analysis  and  cost-effectiveness  analysis[J].
          [15]  国家卫生健康委员会医政医管局 . 原发性肝癌诊疗指                         Front Pharmacol,2022,13:891008.
              南 :2022 年 版 [J].  中 华 肝 脏 病 杂 志 ,2022,30(4):   [23]  VERMERSCH  P,MARTINELLI V,PFLEGER  C,et  al.
              367-388.                                            Benefit-risk  assessment  of  cladribine  using  multi-criteria
              Department  of  Medical  Administration,National  Health   decision  analysis (MCDA)  for  patients  with  relapsing-
              Commission. Standardization for diagnosis and treatment   remitting  multiple  sclerosis[J].  Clin  Ther,2019,41(2):
              of hepatocellular carcinoma:2022 edition[J]. Chin J Hepa‐  249-260.e18.
              tol,2022,30(4):367-388.                        [24]  SU D,WU B,SHI L. Cost-effectiveness of atezolizumab
          [16]  王汝龙. 中国药品综合评价指南参考大纲:第二版第七                         plus  bevacizumab  vs  sorafenib  as  first-line  treatment  of
              章:药物临床价值综合评价指南[J]. 药品评价,2015,12                     unresectable  hepatocellular  carcinoma[J].  JAMA  Netw
              (8):19-20.                                          Open,2021,4(2):e210037.
              WANG  R  L.  Reference  outline  of  comprehensive  evalu-   [25]  ZHAO M Y,PAN X M,YIN Y,et al. Cost-effectiveness
              ation guidelines for drugs in China:chapter Ⅶ of second   analysis of five systemic treatments for unresectable hepa‐
              edition:comprehensive  evaluation  guidelines  for  clinical   tocellular  carcinoma  in  China:an  economic  evaluation
              value of drugs[J]. Drug Eval,2015,12(8):19-20.      based  on  network  meta-analysis[J].  Front  Public  Health,
          [17]  张天嵩,董圣杰,杨智荣,等. 网络Meta分析研究进展系                      2022,10:869960.
              列:十三:生存数据的网络 Meta 分析[J]. 中国循证心血                               (收稿日期:2024-01-21  修回日期:2024-06-19)
              管医学杂志,2021,13(6):649-652.                                                           (编辑:陈 宏)
              ZHANG  T  S,DONG  S  J,YANG  Z  R,et  al.  Network










          中国药房  2024年第35卷第15期                                              China Pharmacy  2024 Vol. 35  No. 15    · 1881 ·
   86   87   88   89   90   91   92   93   94   95   96